白蛋白尿与肺功能下降及新发慢阻肺风险:NHLBI汇总队列研究
该研究汇总6个美国人群队列,在肺功能保留的参与者中分析白蛋白尿与肺功能下降及新发慢性下呼吸道疾病的关系。结果显示,白蛋白尿每增加1个SD,FEV1下降更快、FEV1/FVC下降更显著,新发 spirometry 定义的中重度慢阻肺风险及慢阻肺相关住院/死亡风险均升高,而哮喘事件无显著关联。
要点
- 白蛋白尿水平越高,肺功能下降越快,新发慢阻肺风险越高。
- 白蛋白尿与慢阻肺相关住院/死亡风险增加独立相关。
- 白蛋白尿与哮喘事件无显著关联。
核心结论
- 在美国人群样本中,白蛋白尿与肺功能下降更快、新发 spirometry 定义慢阻肺及慢阻肺相关事件风险升高相关。
研究设计与样本
- 汇总6个美国人群队列,排除已有临床肺病者,测量尿白蛋白/肌酐比值,肺功能用肺量计评估,事件经裁定和/或行政标准分类。
- 分析采用混合模型和比例风险模型,调整年龄、身高、体重、性别、种族/族裔、教育、出生年份、队列、吸烟状态、包年、肾功能、高血压、糖尿病和药物。
- 肺功能分析纳入10,961名肺功能保留的参与者,事件分析纳入14,213名参与者。
主要发现
- 在10,961名参与者中,白蛋白尿测量时平均年龄60岁,51%为从不吸烟者,白蛋白尿中位数5.6 mg/g,平均FEV1年下降31.5 ml。
- 对数转换白蛋白尿每增加1个SD,FEV1下降多2.81%(95%CI 0.86-4.76%,P=0.0047),FEV1/FVC下降多11.02%(95%CI 4.43-17.62%,P=0.0011)。
- 对数转换白蛋白尿每增加1个SD,新发 spirometry 定义的中重度慢阻肺风险增加15%(95%CI 2-31%,P=0.0021)。
- 在14,213名事件随访参与者中,对数转换白蛋白尿每增加1个SD,慢阻肺相关住院/死亡风险增加26%(95%CI 18-34%,P<0.0001)。
- 哮喘事件与白蛋白尿无显著关联。
临床怎么用
- 在呼吸科评估肺功能下降和慢阻肺风险时,可关注白蛋白尿这一内皮损伤生物标志物。
- 对白蛋白尿升高的患者,即使无当前吸烟、糖尿病、高血压或心血管病,也应注意慢阻肺相关事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Chronic lower respiratory diseases (CLRDs), including chronic obstructive pulmonary disease (COPD) and asthma, are the fourth leading cause of death. Prior studies suggest that albuminuria, a biomarker of endothelial injury, is increased in patients with COPD. OBJECTIVES: To test whether albuminuria was associated with lung function decline and incident CLRDs. METHODS: Six U.S. population-based cohorts were harmonized and pooled. Participants with prevalent clinical lung disease were excluded. Albuminuria (urine albumin-to-creatinine ratio) was measured in spot samples. Lung function was assessed by spirometry. Incident CLRD-related hospitalizations and deaths were classified via adjudication and/or administrative criteria. Mixed and proportional hazards models were used to test individual-level associations adjusted for age, height, weight, sex, race/ethnicity, education, birth year, cohort, smoking status, pack-years of smoking, renal function, hypertension, diabetes, and medications. MEASUREMENTS AND MAIN RESULTS: Among 10,961 participants with preserved lung function, mean age at albuminuria measurement was 60 years, 51% were never-smokers, median albuminuria was 5.6 mg/g, and mean FEV1 decline was 31.5 ml/yr. For each SD increase in log-transformed albuminuria, there was 2.81% greater FEV1 decline (95% confidence interval [CI], 0.86-4.76%; P = 0.0047), 11.02% greater FEV1/FVC decline (95% CI, 4.43-17.62%; P = 0.0011), and 15% increased hazard of incident spirometry-defined moderate-to-severe COPD (95% CI, 2-31%, P = 0.0021). Each SD log-transformed albuminuria increased hazards of incident COPD-related hospitalization/mortality by 26% (95% CI, 18-34%, P < 0.0001) among 14,213 participants followed for events. Asthma events were not significantly associated. Associations persisted in participants without current smoking, diabetes, hypertension, or cardiovascular disease. CONCLUSIONS: Albuminuria was associated with greater lung function decline, incident spirometry-defined COPD, and incident COPD-related events in a U.S. population-based sample.
引用
- Oelsner EC, Balte PP, Grams ME, et al. Albuminuria, Lung Function Decline, and Risk of Incident Chronic Obstructive Pulmonary Disease. The NHLBI Pooled Cohorts Study. Am J Respir Crit Care Med. 2019. PMID: 30261735. doi:10.1164/rccm.201803-0402OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。